Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri for Crohn’s gets FDA advisory review

Executive Summary

FDA's Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees will jointly review Biogen Idec/Elan's Tysabri (natalizumab) for moderately to severely active Crohn's disease July 31. Indicated for multiple sclerosis, Tysabri's sNDA includes results of three trials assessing the biologic as both an induction and maintenance therapy. Biogen pulled Tysabri from the market in 2005 after reports of progressive multifocal leukoencephalopathy, and the company is now in the second phase of the drug's relaunch. One of the three reported cases of PML in the Tysabri database was in a Crohn's patient...

You may also be interested in...



Submitting A Non-COVID-19 Product For FDA Review? Then Take A Seat, It’s Gonna Be Awhile

Top US FDA device center officials Jeff Shuren and William Maisel said in a 15 April blog post that manufacturers should expect a delay in the review of new product submissions thanks to the pandemic. They noted that the agency also won’t be accepting certain IVD pre-submission requests until next year.

Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board

Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.

In Flood Of 2020 Sanitizer Launches, Unilever’s Suave Brand Tops US Category Sales

Unilever’s Suave brand led new sanitizer product sales in 2020, when hand sanitizers total sales grew 569%, according to IRI. Sales of rinseable hand-soap sales grew 64% and antiseptics 19%.

UsernamePublicRestriction

Register

PS048437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel